Cargando…

Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors

INTRODUCTION: Self-report instruments such as the Impact of Cancer (IOC) are designed to measure quality of life (QOL) impacts that cancer survivors attribute to their cancer experience. Generalizability of QOL findings across distinct diagnostic categories of survivors is untested. We compare measu...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespi, Catherine M., Smith, Sophia K., Petersen, Laura, Zimmerman, Sheryl, Ganz, Patricia A.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813525/
https://www.ncbi.nlm.nih.gov/pubmed/19967410
http://dx.doi.org/10.1007/s11764-009-0106-1
_version_ 1782176915996540928
author Crespi, Catherine M.
Smith, Sophia K.
Petersen, Laura
Zimmerman, Sheryl
Ganz, Patricia A.
author_facet Crespi, Catherine M.
Smith, Sophia K.
Petersen, Laura
Zimmerman, Sheryl
Ganz, Patricia A.
author_sort Crespi, Catherine M.
collection PubMed
description INTRODUCTION: Self-report instruments such as the Impact of Cancer (IOC) are designed to measure quality of life (QOL) impacts that cancer survivors attribute to their cancer experience. Generalizability of QOL findings across distinct diagnostic categories of survivors is untested. We compare measurement of the impact of cancer using the IOC instrument in breast cancer (BC) survivors (n = 1,188) and non-Hodgkin lymphoma (NHL) survivors (n = 652). METHODS: A registry-based sample of NHL survivors completed the IOC questionnaire and the FACT-G, FACT-LYM, Medical Outcomes Study (MOS) SF-36, Post-Traumatic Stress Disorder Checklist-Civilian Version, Post-Traumatic Growth Inventory and MOS Social Support scales. IOC responses of the NHL survivors were subjected to de novo scaling to identify impact domains for comparison to IOC version 2 (IOCv2) domains, which were previously developed based on BC survivor responses. Concurrent validity was assessed by correlating the IOCv2 scales with the other measures. IOCv2 scores were compared between the BC and NHL survivor samples. RESULTS: The BC and NHL survivors exhibited similar impact domains and had factor structures that were largely congruent. The concurrent validity analysis revealed patterns of association that supported the interpretation and validity of the IOCv2 scales. Differences in IOCv2 scores between the BC and NHL groups suggested differential impacts in distinct survivor groups that could be detected using the IOCv2. CONCLUSION: The results suggest that the IOCv2 measures common and important survivor concerns and support its generalizability to the broader long-term cancer survivor population. IMPLICATIONS FOR CANCER SURVIVORS: Instruments such as the IOCv2 can provide valid assessment of QOL impacts in long-term cancer survivors, facilitating the characterization of these impacts and development of appropriate interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11764-009-0106-1) contains supplementary material, which is available to authorized users.
format Text
id pubmed-2813525
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-28135252010-02-13 Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors Crespi, Catherine M. Smith, Sophia K. Petersen, Laura Zimmerman, Sheryl Ganz, Patricia A. J Cancer Surviv Article INTRODUCTION: Self-report instruments such as the Impact of Cancer (IOC) are designed to measure quality of life (QOL) impacts that cancer survivors attribute to their cancer experience. Generalizability of QOL findings across distinct diagnostic categories of survivors is untested. We compare measurement of the impact of cancer using the IOC instrument in breast cancer (BC) survivors (n = 1,188) and non-Hodgkin lymphoma (NHL) survivors (n = 652). METHODS: A registry-based sample of NHL survivors completed the IOC questionnaire and the FACT-G, FACT-LYM, Medical Outcomes Study (MOS) SF-36, Post-Traumatic Stress Disorder Checklist-Civilian Version, Post-Traumatic Growth Inventory and MOS Social Support scales. IOC responses of the NHL survivors were subjected to de novo scaling to identify impact domains for comparison to IOC version 2 (IOCv2) domains, which were previously developed based on BC survivor responses. Concurrent validity was assessed by correlating the IOCv2 scales with the other measures. IOCv2 scores were compared between the BC and NHL survivor samples. RESULTS: The BC and NHL survivors exhibited similar impact domains and had factor structures that were largely congruent. The concurrent validity analysis revealed patterns of association that supported the interpretation and validity of the IOCv2 scales. Differences in IOCv2 scores between the BC and NHL groups suggested differential impacts in distinct survivor groups that could be detected using the IOCv2. CONCLUSION: The results suggest that the IOCv2 measures common and important survivor concerns and support its generalizability to the broader long-term cancer survivor population. IMPLICATIONS FOR CANCER SURVIVORS: Instruments such as the IOCv2 can provide valid assessment of QOL impacts in long-term cancer survivors, facilitating the characterization of these impacts and development of appropriate interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11764-009-0106-1) contains supplementary material, which is available to authorized users. Springer US 2009-12-06 2010 /pmc/articles/PMC2813525/ /pubmed/19967410 http://dx.doi.org/10.1007/s11764-009-0106-1 Text en © The Author(s) 2009 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Crespi, Catherine M.
Smith, Sophia K.
Petersen, Laura
Zimmerman, Sheryl
Ganz, Patricia A.
Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title_full Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title_fullStr Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title_full_unstemmed Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title_short Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors
title_sort measuring the impact of cancer: a comparison of non-hodgkin lymphoma and breast cancer survivors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813525/
https://www.ncbi.nlm.nih.gov/pubmed/19967410
http://dx.doi.org/10.1007/s11764-009-0106-1
work_keys_str_mv AT crespicatherinem measuringtheimpactofcanceracomparisonofnonhodgkinlymphomaandbreastcancersurvivors
AT smithsophiak measuringtheimpactofcanceracomparisonofnonhodgkinlymphomaandbreastcancersurvivors
AT petersenlaura measuringtheimpactofcanceracomparisonofnonhodgkinlymphomaandbreastcancersurvivors
AT zimmermansheryl measuringtheimpactofcanceracomparisonofnonhodgkinlymphomaandbreastcancersurvivors
AT ganzpatriciaa measuringtheimpactofcanceracomparisonofnonhodgkinlymphomaandbreastcancersurvivors